Late last year, The Jewish Hospital-Mercy Health in Cincinnati received a first-place award in a multi-state competition for its efforts to reduce Clostridium difficile infections among inpatients.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min C. diff is the leading cause of ...

Please provide your email address to receive an email when new articles are posted on . Clostridioides difficile infection presents a unique treatment paradox for clinicians: Antibiotics are often ...

In a phase-one human clinical trial, a pharmacist researcher has demonstrated that a new antibiotic, called Omadacycline, may be a promising tool in combating the superbug known as C diff which causes ...

Bethesda, MD (Feb. 21, 2024) — In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological ...

The pathogen C. diff—the most common cause of health care-associated infectious diarrhea—can use a compound that kills the human gut's resident microbes to survive and grow, giving it a competitive ...

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...